Dova Pharmaceuticals’ (NASDAQ:DOVA) lock-up period will expire on Tuesday, December 26th. Dova Pharmaceuticals had issued 4,415,000 shares in its IPO on June 29th. The total size of the offering was $75,055,000 based on an initial share price of $17.00. After the expiration of Dova Pharmaceuticals’ lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

A number of equities research analysts have commented on DOVA shares. Zacks Investment Research raised shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price objective on the stock in a research report on Wednesday, October 11th. Leerink Swann raised shares of Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 price objective on the stock in a research report on Tuesday, September 26th. Finally, Jefferies Group increased their price objective on shares of Dova Pharmaceuticals to $33.00 and gave the company a “buy” rating in a research report on Tuesday, November 28th.

Dova Pharmaceuticals (NASDAQ:DOVA) opened at $28.50 on Thursday. Dova Pharmaceuticals has a twelve month low of $16.98 and a twelve month high of $32.75.

Dova Pharmaceuticals (NASDAQ:DOVA) last issued its earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.08). During the same quarter last year, the business posted ($0.41) EPS. analysts forecast that Dova Pharmaceuticals will post -1.51 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of DOVA. California State Teachers Retirement System acquired a new position in shares of Dova Pharmaceuticals in the 3rd quarter valued at $202,000. Laurion Capital Management LP acquired a new position in shares of Dova Pharmaceuticals in the 2nd quarter valued at $223,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Dova Pharmaceuticals in the 3rd quarter valued at $241,000. Bank of New York Mellon Corp acquired a new position in shares of Dova Pharmaceuticals in the 3rd quarter valued at $340,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Dova Pharmaceuticals in the 2nd quarter valued at $382,000. Institutional investors and hedge funds own 26.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Dova Pharmaceuticals Inc’s Lock-Up Period To Expire on December 26th (NASDAQ:DOVA)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/12/21/dova-pharmaceuticals-incs-lock-up-period-to-expire-on-december-26th-nasdaqdova.html.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.